CRISPR Therapeutics AG (CRSP) shareholders
Close on Nov 17, 2026Market cap $3.88BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Catherine D. Wood Joint filing with ARK Investment Management LLC (11.79%) | 11,313,623 | 11.79% | 13G (passive) amendment | Mar 31, 2026 |
| ARK Investment Management LLC Joint filing with Catherine D. Wood (11.85%) | 10,165,400 | 11.85% | 13G (passive) amendment | Mar 31, 2025 |
| BlackRock, Inc. | 7,987,262 | 8.30% | 13G (passive) amendment | Jun 30, 2026 |
| Orbis Investment Management Ltd | 5,433,344 | 5.60% | 13G (passive) amendment | Jun 30, 2026 |
| State Street Corporation | 4,994,047 | 5.20% | 13G (passive) | Sep 30, 2026 |
| Capital World Investors | 4,929,428 | 5.10% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CRSP | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| ARK Investment Management LLC | 9,460,939 | 9.78% | $516.00M | −1,852,684 | 3.35% |
| BlackRock, Inc. | 8,348,977 | 8.63% | $455.35M | +668,904 | 0.01% |
| Orbis Allan Gray Ltd | 5,449,161 | 5.64% | $297.20M | −656,850 | 1.02% |
| Capital World Investors | 4,749,525 | 4.91% | $259.04M | +24,488 | 0.03% |
| State Street Corp | 4,321,666 | 4.47% | $235.70M | +339,166 | 0.01% |
| GSK plc | 3,220,627 | 3.33% | $175.65M | – | 29.17% |
| Geode Capital Management, LLC | 2,509,915 | 2.60% | $136.92M | +132,751 | 0.01% |
| T. Rowe Price Investment Management, Inc. | 2,053,017 | 2.12% | $111.97M | −899,578 | 0.07% |
| Sr One Capital Management, LP | 2,038,763 | 2.11% | $111.19M | – | 10.70% |
| Two Sigma Investments, LP | 1,988,621 | 2.06% | $108.46M | +505,570 | 0.08% |
| FMR LLC | 1,908,503 | 1.97% | $104.09M | −46,191 | 0.00% |
| Sumitomo Mitsui Trust Holdings, Inc. | 1,720,734 | 1.78% | $93.85M | −133,141 | 0.05% |
| Nikko Asset Management Americas, Inc. | 1,720,097 | 1.78% | $93.76M | −133,778 | 1.21% |
| EcoR1 Capital, LLC | 1,389,276 | 1.44% | $75.77M | – | 3.68% |
| UBS Group AG | 1,317,499 | 1.36% | $71.86M | −445,031 | 0.01% |
| Capital International Investors | 1,268,407 | 1.31% | $69.18M | +81,613 | 0.01% |
| Vanguard Capital Management LLC | 1,181,847 | 1.22% | $64.46M | +39,304 | 0.00% |
| Bank Of America Corp /De/ | 1,155,105 | 1.19% | $63.00M | +172,033 | 0.00% |
| NEA Management Company, LLC | 1,058,570 | 1.09% | $57.73M | – | 3.64% |
| Charles Schwab Investment Management Inc | 1,057,837 | 1.09% | $57.69M | +18,488 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 522 | 76M | 78.9% | 82 / 156 | 142 / 47 | 6M | 7M |
| Q1 2026 | 493 | 77M | 79.8% | 80 / 176 | 117 / 58 | 13M | 12M |
| Q4 2025 | 480 | 78M | 81.1% | 96 / 150 | 128 / 52 | 11M | 5M |
| Q3 2025 | 440 | 73M | 75.3% | 73 / 146 | 120 / 58 | 9M | 9M |
| Q2 2025 | 433 | 73M | 75.3% | 101 / 127 | 101 / 60 | 15M | 7M |
| Q1 2025 | 396 | 65M | 66.9% | 55 / 123 | 102 / 59 | 8M | 8M |
| Q4 2024 | 404 | 65M | 66.8% | 66 / 114 | 122 / 70 | 10M | 5M |
| Q3 2024 | 416 | 60M | 62.3% | 45 / 132 | 131 / 73 | 7M | 4M |
| Q2 2024 | 449 | 60M | 62.0% | 49 / 159 | 129 / 75 | 5M | 7M |
| Q1 2024 | 482 | 62M | 63.9% | 74 / 159 | 137 / 57 | 11M | 6M |
| Q4 2023 | 472 | 56M | 58.4% | 120 / 136 | 124 / 45 | 6M | 5M |
| Q3 2023 | 407 | 55M | 56.8% | 45 / 157 | 100 / 52 | 3M | 3M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Samarth Kulkarni | Chief Executive Officer, Director | 397,521 | 0.41% | Oct 28, 2026 |
| Sivakesava Sakhamuri | Chief Technical Officer | – | – | Nov 6, 2026 |
| Naimish Patel | Chief Medical Officer | 19,357 | 0.02% | Oct 28, 2026 |
| James R. Kasinger | General Counsel and Secretary | 95,857 | 0.10% | Oct 28, 2026 |
| Andrew Jacob Silver | Chief Financial Officer | – | – | Oct 28, 2026 |
| Raju Prasad | Chief Financial Officer | 14,815 | 0.02% | Aug 11, 2026 |
| Julianne Bruno | Chief Operating Officer | 17,632 | 0.02% | Mar 24, 2025 |
| Simeon George | Director | 2,054,249 | 2.12% | Oct 16, 2026 |
| Ali Behbahani | Director | 345 | 0.00% | Sep 21, 2026 |
| John Greene | Director | 7,000 | 0.01% | Jun 9, 2026 |
| Katherine A. High | Director | – | – | Jun 9, 2026 |
| Douglas A. Treco | Director | 22,000 | 0.02% | Jun 9, 2026 |
| Briggs Morrison | Director | 5,209 | 0.01% | Jun 9, 2026 |
| Christian Rommel | Director | – | – | Jun 9, 2026 |
| Sandesh Mahatme | Director | – | – | Jun 9, 2026 |
| Maria Fardis | Director | – | – | Jun 9, 2026 |
| Harold Edward Fleming | Director | – | – | Jun 9, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Samarth Kulkarni Chief Executive Officer, Director | Oct 19, 2026 | Sale | −47,837 | $49.78 | $2.38M | 311,899 |
| Samarth Kulkarni Chief Executive Officer, Director | Oct 16, 2026 | Option exercise | +100,000 | – | – | 359,736 |
| Simeon George Director | Oct 14, 2026 | Sale(10b5-1 plan) | −14,514 | $49.63 | $720.37K | 15,486 |
| Simeon George Director | Oct 14, 2026 | Option exercise | +30,000 | $14.00 | $420.00K | 30,000 |
| James R. Kasinger General Counsel and Secretary | Oct 14, 2026 | Sale | −1,040 | $49.26 | $51.23K | 95,857 |
| Samarth Kulkarni Chief Executive Officer, Director | Oct 14, 2026 | Sale | −4,098 | $49.26 | $201.87K | 259,736 |
| James R. Kasinger General Counsel and Secretary | Oct 13, 2026 | Option exercise | +2,113 | – | – | 96,897 |
| Samarth Kulkarni Chief Executive Officer, Director | Oct 13, 2026 | Option exercise | +8,333 | – | – | 263,834 |
| James R. Kasinger General Counsel and Secretary | Oct 6, 2026 | Sale(10b5-1 plan) | −1,990 | $60.04 | $119.48K | 94,784 |
| James R. Kasinger General Counsel and Secretary | Oct 6, 2026 | Option exercise | +1,990 | $13.62 | $27.10K | 96,774 |
| James R. Kasinger General Counsel and Secretary | Sep 22, 2026 | Option exercise | +10,400 | $13.62 | $141.65K | 105,184 |
| James R. Kasinger General Counsel and Secretary | Sep 22, 2026 | Sale(10b5-1 plan) | −10,400 | $60.24 | $626.50K | 94,784 |
| Ali Behbahani Director | Sep 17, 2026 | Option exercise | +30,000 | $14.00 | $420.00K | 30,316 |
| Ali Behbahani Director | Sep 17, 2026 | Sale | −13,679 | $57.09 | $780.93K | 16,637 |
| Raju Prasad Chief Financial Officer | Aug 7, 2026 | Gift | −750 | – | – | 14,815 |
| Naimish Patel Chief Medical Officer | May 29, 2026 | Sale | −3,786 | $55.62 | $210.58K | 19,357 |
| Naimish Patel Chief Medical Officer | May 28, 2026 | Option exercise | +10,000 | – | – | 23,143 |
| Raju Prasad Chief Financial Officer | Mar 23, 2026 | Sale | −3,708 | $46.78 | $173.46K | 15,565 |
| James R. Kasinger General Counsel and Secretary | Mar 23, 2026 | Sale | −3,182 | $46.78 | $148.85K | 94,308 |
| Samarth Kulkarni Chief Executive Officer, Director | Mar 23, 2026 | Sale | −10,020 | $46.78 | $468.74K | 255,501 |
| Raju Prasad Chief Financial Officer | Mar 20, 2026 | Option exercise | +6,250 | – | – | 19,273 |
| James R. Kasinger General Counsel and Secretary | Mar 20, 2026 | Option exercise | +6,250 | – | – | 97,490 |
| Samarth Kulkarni Chief Executive Officer, Director | Mar 20, 2026 | Option exercise | +19,687 | – | – | 265,521 |
| Raju Prasad Chief Financial Officer | Mar 16, 2026 | Sale | −4,021 | $48.26 | $194.05K | 13,773 |
| Raju Prasad Chief Financial Officer | Mar 16, 2026 | Gift | −750 | – | – | 13,023 |
| Raju Prasad Chief Financial Officer | Mar 16, 2026 | Sale | −5,848 | $48.26 | $282.22K | 17,794 |
| Naimish Patel Chief Medical Officer | Mar 16, 2026 | Sale | −3,150 | $48.26 | $152.02K | 13,143 |
| Samarth Kulkarni Chief Executive Officer, Director | Mar 16, 2026 | Sale | −10,349 | $48.26 | $499.44K | 245,834 |
| James R. Kasinger General Counsel and Secretary | Mar 16, 2026 | Sale | −3,450 | $48.26 | $166.50K | 91,240 |
| Raju Prasad Chief Financial Officer | Mar 14, 2026 | Option exercise | +10,000 | – | – | 16,767 |
| Raju Prasad Chief Financial Officer | Mar 14, 2026 | Option exercise | +6,875 | – | – | 23,642 |
| Naimish Patel Chief Medical Officer | Mar 14, 2026 | Option exercise | +8,125 | – | – | 16,293 |
| Samarth Kulkarni Chief Executive Officer, Director | Mar 14, 2026 | Option exercise | +20,625 | – | – | 256,183 |
| James R. Kasinger General Counsel and Secretary | Mar 14, 2026 | Option exercise | +6,875 | – | – | 94,690 |
| Samarth Kulkarni Chief Executive Officer, Director | Mar 11, 2026 | Sale | −9,798 | $52.80 | $517.33K | 235,558 |
| James R. Kasinger General Counsel and Secretary | Mar 11, 2026 | Sale | −2,800 | $52.80 | $147.84K | 87,815 |
| Samarth Kulkarni Chief Executive Officer, Director | Mar 10, 2026 | Option exercise | +19,250 | – | – | 245,356 |
| James R. Kasinger General Counsel and Secretary | Mar 10, 2026 | Option exercise | +5,500 | – | – | 90,615 |
| James R. Kasinger General Counsel and Secretary | Feb 19, 2026 | Sale | −2,112 | $52.58 | $111.05K | 85,115 |
| Samarth Kulkarni Chief Executive Officer, Director | Feb 19, 2026 | Sale | −6,967 | $52.58 | $366.32K | 226,106 |
| James R. Kasinger General Counsel and Secretary | Feb 18, 2026 | Option exercise | +3,825 | – | – | 87,227 |
| Samarth Kulkarni Chief Executive Officer, Director | Feb 18, 2026 | Option exercise | +13,250 | – | – | 233,073 |
| Raju Prasad Chief Financial Officer | Jan 22, 2026 | Sale(10b5-1 plan) | −34,972 | $60.19 | $2.10M | 6,767 |
| Raju Prasad Chief Financial Officer | Jan 22, 2026 | Option exercise | +34,972 | $45.15 | $1.58M | 41,739 |
| Samarth Kulkarni Chief Executive Officer, Director | Jan 22, 2026 | Sale(10b5-1 plan) | −60,000 | $60.23 | $3.61M | 134,201 |
| Samarth Kulkarni Chief Executive Officer, Director | Jan 20, 2026 | Sale(10b5-1 plan) | −8,567 | $52.10 | $446.34K | 194,201 |
| Samarth Kulkarni Chief Executive Officer, Director | Jan 20, 2026 | Sale(10b5-1 plan) | −21,433 | $51.61 | $1.11M | 202,768 |
| Raju Prasad Chief Financial Officer | Jan 6, 2026 | Sale(10b5-1 plan) | −18,933 | $60.18 | $1.14M | 17,534 |
| Raju Prasad Chief Financial Officer | Jan 6, 2026 | Sale(10b5-1 plan) | −5,004 | $60.00 | $300.24K | 12,530 |
| Raju Prasad Chief Financial Officer | Jan 6, 2026 | Sale(10b5-1 plan) | −5,763 | $60.21 | $346.99K | 6,767 |
| Raju Prasad Chief Financial Officer | Jan 6, 2026 | Option exercise | +6,339 | $44.31 | $280.88K | 36,467 |
| Raju Prasad Chief Financial Officer | Jan 6, 2026 | Option exercise | +23,361 | $45.15 | $1.05M | 30,128 |
| Raju Prasad Chief Financial Officer | Dec 22, 2025 | Sale(10b5-1 plan) | −5,472 | $56.33 | $308.24K | 7,767 |
| Raju Prasad Chief Financial Officer | Dec 22, 2025 | Sale(10b5-1 plan) | −1,000 | $56.89 | $56.89K | 6,767 |
| Raju Prasad Chief Financial Officer | Dec 22, 2025 | Sale(10b5-1 plan) | −3,528 | $55.10 | $194.39K | 13,239 |
| Samarth Kulkarni Chief Executive Officer, Director | Dec 18, 2025 | Gift | −30,000 | – | – | 224,201 |
| Samarth Kulkarni Chief Executive Officer, Director | Oct 17, 2025 | Sale | −50,895 | $67.91 | $3.46M | 254,201 |
| Samarth Kulkarni Chief Executive Officer, Director | Oct 16, 2025 | Option exercise | +100,000 | – | – | 305,096 |
| James R. Kasinger General Counsel and Secretary | Oct 14, 2025 | Sale | −1,076 | $66.60 | $71.66K | 83,402 |
| Samarth Kulkarni Chief Executive Officer, Director | Oct 14, 2025 | Sale | −4,242 | $66.60 | $282.52K | 205,096 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of CRISPR Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 36,884 shares on Oct 7, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Raju Prasad Officer | Nov 6, 2026 | 79,393 | $3.96M | Nov 6, 2026 | Stock Option Exercise |
| Simeon George Director | Oct 14, 2026 | 14,514 | $720.37K | Oct 14, 2026 | Stock Option Exercise |
| James R. Kasinger Officer | Oct 6, 2026 | 1,990 | $119.48K | Oct 6, 2026 | Stock Option Exercise |
| James R. Kasinger Officer | Sep 22, 2026 | 10,400 | $626.46K | Sep 22, 2026 | Stock Option Exercise |
| Ali Behbahani Director | Sep 17, 2026 | 13,679 | $780.94K | Sep 17, 2026 | Stock Option Exercise |
| Raju Prasad Officer | Jan 22, 2026 | 34,972 | $2.11M | Jan 22, 2026 | Stock Option Exercise |
| Samarth Kulkarni Officer | Jan 22, 2026 | 60,000 | $3.65M | Jan 22, 2026 | Acquired as compensation -- Restricted Stock Awards |
| Samarth Kulkarni Officer | Jan 20, 2026 | 30,000 | $1.58M | Jan 20, 2026 | Acquired as compensation -- Restricted Stock Awards |
| Raju Prasad Officer | Jan 6, 2026 | 29,700 | $1.79M | Jan 6, 2026 | Stock Option Exercise |
| Raju Prasad Officer | Dec 22, 2025 | 10,000 | $559.55K | Dec 22, 2025 | Restricted Stock |
| Samarth Kulkarni Officer | Feb 18, 2025 | 45,000 | $2.35M | Feb 18, 2025 | Acquired as compensation -- Restricted Stock Awards |
| Samarth Kulkarni Officer | Nov 12, 2024 | 75,000 | $4.11M | Nov 11, 2024 | Acquired as compensation -- Restricted Stock Awards |
| Samarth Kulkarni Officer, Director | Apr 15, 2024 | 19,582 | $1.17M | Apr 15, 2024 | Stock Option Exercise |
| Phuong Khanh Morrow Officer | Mar 22, 2024 | 50,767 | $3.70M | Mar 22, 2024 | Stock Option Exercise |
| Samarth Kulkarni Officer, Director | Mar 15, 2024 | 20,000 | $1.45M | Mar 15, 2024 | Stock Option Exercise |
See a number that looks wrong?